(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Vote In favor of Your Favored Kind Of Cheddar - 2The 10 Most Famous Style Minutes on Honorary pathway
- 3Lebanon says Israeli strike killed 13 people near Palestinian refugee camp
- 4Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video)
- 5Instructions to Utilize the Towing Highlights of the Slam 1500 Productively.
- Savvy Watches: Which One Is Appropriate for You?
- The Magnificence of Do-It-Yourself Skincare: Regular Recipes and Tips
- 3D Printers for Specialists
- How color-changing, bacteria-infused spacesuits could help keep future astronauts safe from space radiation
- Pick Your Favored pizza beating
- Danish warship sunk by famed British admiral discovered after 225 years
- Vote In favor of Your Favored Shimmering Water
- Instructions to Really Oversee Unsold SUVs in the Auto Business
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
